Aslan Pharmaceuticals Ltd(ASLN)stock report

ASLAN Pharmaceuticals Limited, incorporated in the cayman islands in June 2014, is a clinical oncology focused biopharmaceutical company headquartered in Singapore that develops novel therapeutic drugs for the global market. The company targets highly prevalent diseases in Asia as well as orphan symptoms in the United States and Europe. The company’s Asian development platform is designed to allow them to accelerate the development of drugs to treat these diseases. The company’s portfolio includes four product candidates whose objectives are: proven growth pathways for new patient segments; Novel immune checkpoints; And new metabolic pathways in cancer.

Finance:
Q3 2019(9/30/19): Cash 7.99M. Loss 5.18M

EPS and Sales:
https://finance.yahoo.com/quote/ASLN/financials?p=ASLN

Date EPS % last year % last quarter
2018.12.31 -0.21 / -50.00%
2019.3.31 -0.99 14.85% -371.43%
2019.6.30 -0.8 -471.43% 118.00%
2019.9.30 -0.11 47.62% 86.25%

 

Date Sales % last year % last quarter
2018.12.31 / / /
2019.3.31 / / /
2019.6.30 3M / /
2019.9.30 / / /

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=ASLN&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/ASLN/institutional-ownership/

2019.12.20:
Total institutions: 8,no change
Shares hold: 2281.9k shares. no change
shares% hold: 6.14%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/ASLN/price-targe

Leave a Reply